International Journal of Drug Policy
July 1, 2026
Salim Mezaache, Liselotte Pochard, Hélène Peyrière et al.
Ketamine analogues are emerging dissociative substances structurally related to ketamine and increasingly detected on drug markets worldwide. This study aimed to characterize patterns of use, user profiles, and associated health outcomes in France. We conducted a retrospective analysis of cases involving ketamine analogues reported to the French Addictovigilance Network up to 31 December 2024....
Journal of Psychopharmacology
February 23, 2026
Tiphaine Raingeard, Thomas Soeiro, Caroline Victorri-Vigneau et al.
Background: While ketamine is widely used in anesthesia and pain management, its non-medical use is increasing worldwide. In France, surveillance data indicate a sharp rise in ketamine-related disorders, but comprehensive characterization of affected patients and associated complications remains limited. Aims: To examine trends on ketamine in France from 2019 to 2023, and describe severe...
Harm Reduction Journal
July 28, 2023
Théo Willeman, Nathan Grundig, Christine Pochon et al.
8 citations
3-methylmethcathinone (3-MMC) has been available on the European drug market for several years, but an increase in its availability seems to have occurred around 2020, associated with reports of harm and death. We aimed to analyze the composition of the supposed 3-MMC samples purchased and its concordance with the assumed composition of the drug. A prospective multicenter (n = 6) study was...
British Journal of Clinical Pharmacology
November 1, 2022
Bruno Revol, Maryse Lapeyre-Mestre, Nathalie Fouilhé Sam-Lai et al.
Ketamine and dextromethorphan are widely abused psychoactive substances. Inhibition of N-methyl-d-aspartate receptors (NMDARs) results in neurobehavioural effects including hallucinations, "out of body" sensations and dissociative effects. However, little is known about a possible extended addictive class effect linked to pharmacologically-related amino-adamantane derivatives (e.g., amantadine...